C-type Natriuretic peptide (CNP): Cardiovascular roles and potential as a therapeutic target

Current Pharmaceutical Design

Volumn 16, Issue 37, 2010, Pages 4080-4088

  Lumsden, Natalie G ^a   Khambata, Rayomand S ^b   Hobbs, Adrian J ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular disease; Endothelium; Leukocyte; Natriuretic peptide; Platelet; Vasodilatation

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; CD40 LIGAND; COLONY STIMULATING FACTOR RECEPTOR; CORTICOTROPIN; CYCLIC GMP; ENDOTHELIN RECEPTOR ANTAGONIST; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; FIBROBLAST GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN DERIVATIVE; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASOPRESSIN;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BARE METAL STENT; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; BONE DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CAROTID ARTERY OBSTRUCTION; CHROMOSOME 5; CHROMOSOME 9; DRUG DESIGN; DRUG ELUTING STENT; DRUG POTENCY; DRUG TARGETING; DWARFISM; GENE; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; NEOINTIMA; NONHUMAN; NPPB GENE; PEPTIDE SYNTHESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN STRUCTURE; PULMONARY HYPERTENSION; REGULATORY MECHANISM; RESTENOSIS; REVASCULARIZATION; SIGNAL TRANSDUCTION; STENT THROMBOSIS; VASCULAR SMOOTH MUSCLE; VASODILATATION; VEIN GRAFT DISEASE;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MOLECULAR TARGETED THERAPY; NATRIURETIC PEPTIDE, C-TYPE; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 79952717185     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794519237     Document Type: Article

References (166)

1. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990;168(2): 863-870.
2. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28(1): 89-94.
3. Stingo AJ, Clavell AL, Heublein DM, Wei CM, Pittelkow MR, Burnett JC, Jr. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol 1992; 263(4 Pt2): H1318-1321.
4. Chen HH, Burnett JC, Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998; 32 (Suppl 3): S22-28.
5. Kalra PR, Anker SD, Struthers AD, Coats AJ. The role of C-type natriuretic peptide in cardiovascular medicine. Eur Heart J 2001; 22(12): 997-1007.
6. Wiley KE, Davenport AP. Physiological antagonism of endothelin- 1 in human conductance and resistance coronary artery. Br J Pharmacol 2001; 133(4): 568-574.
7. Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ. Release of Ctype natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA 2003; 100(3): 1426-1431.
8. Drewett JG, Fendly BM, Garbers DL, Lowe DG. Natriuretic peptide receptor-B (guanylyl cyclase-B) mediates C-type natriuretic peptide relaxation of precontracted rat aorta. J Biol Chem 1995;270(9): 4668-4674.
9. Brunner F, Wolkart G. Relaxant effect of C-type natriuretic peptide involves endothelium and nitric oxide-cGMP system in rat coronary microvasculature. Cardiovasc Res 2001; 51(3): 577-584.
10. Wennberg PW, Miller VM, Rabelink T, Burnett JC, Jr. Further attenuation of endothelium-dependent relaxation imparted by natriuretic peptide receptor antagonism. Am J Physiol 1999; 277(4 Pt2): H1618-H1621.
11. Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ. Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol 2003; 139(7): 1289-1296.
12. Steinmetz M, Potthast R, Sabrane K, Kuhn M. Diverging vasorelaxing effects of C-type natriuretic peptide in renal resistance arteries and aortas of GC-A-deficient mice. Regul Pept 2004; 119(1-2):31-37.
13. Barber DA, Burnett JC, Jr., Fitzpatrick LA, Sieck GC, Miller VM. Gender and relaxation to C-type natriuretic peptide in porcine coronary arteries. J Cardiovasc Pharmacol 1998; 32(1): 5-11.
14. Seymour AA, Mathers PD, Abboa-Offei BE, Asaad MM, Weber H. Renal and depressor activity of C-natriuretic peptide in conscious monkeys: effects of enzyme inhibitors. J Cardiovasc Pharmacol 1996; 28(3): 397-401.
15. Clavell AL, Stingo AJ, Wei CM, Heublein DM, Burnett JC, Jr. Ctype natriuretic peptide: a selective cardiovascular peptide. Am J Physiol 1993; 264(2 Pt 2): R290-295.
16. Honing ML, Smits P, Morrison PJ, Burnett JC, Jr., Rabelink TJ. Ctype natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels. Hypertension 2001; 37(4): 1179-1183.
17. Igaki T, Itoh H, Suga S, et al. C-type natriuretic peptide in chronic renal failure and its action in humans. Kidney Int Suppl 1996; 55:S144-147.
18. Su J, Scholz PM, Weiss HR. Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med (Maywood) 2005; 230(4): 242-250.
19. Pierkes M, Gambaryan S, Boknik P, et al. Increased effects of Ctype natriuretic peptide on cardiac ventricular contractility and relaxation in guanylyl cyclase A-deficient mice. Cardiovasc Res 2002; 53(4): 852-861.
20. Brusq JM, Mayoux E, Guigui L, Kirilovsky J. Effects of C-type natriuretic peptide on rat cardiac contractility. Br J Pharmacol 1999; 128(1): 206-212.
21. Guild SB, Cramb G. Characterisation of the effects of natriuretic peptides upon ACTH secretion from the mouse pituitary. Mol Cell Endocrinol 1999; 152(1-2): 11-9.
22. Shirakami G, Itoh H, Suga S, et al. Central action of C-type natriuretic peptide on vasopressin secretion in conscious rats. Neurosci Lett 1993; 159(1-2): 25-28.
23. Trachte GJ. Depletion of natriuretic peptide C receptors eliminates inhibitory effects of C-type natriuretic peptide on evoked neurotransmitter efflux. J Pharmacol Exp Ther 2000; 294(1): 210-215.
24. Chusho H, Tamura N, Ogawa Y, et al. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 2001; 98(7): 4016-4021.
25. Komatsu Y, Chusho H, Tamura N, et al. Significance of C-type natriuretic peptide (CNP) in endochondral ossification: analysis of CNP knockout mice. J Bone Miner Metab 2002; 20(6): 331-336.
26. Kake T, Kitamura H, Adachi Y, et al. Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice. Am J Physiol Endocrinol Metab 2009; 297(6): E1339-E1348.
27. Schmidt H, Stonkute A, Juttner R, Koesling D, Friebe A, Rathjen FG. C-type natriuretic peptide (CNP) is a bifurcation factor for sensory neurons. Proc Natl Acad Sci USA 2009; 106(39): 16847-16852.
28. Ma J, Yu W, Wang Y, et al. Neuroprotective effects of C-type natriuretic peptide on rat retinal ganglion cells. Invest Ophthalmol Vis Sci 2010; 51(7): 3544-3553.
29. McNeill BA, Barrell GK, Wellby M, Prickett TC, Yandle TG, Espiner EA. C-type natriuretic peptide forms in pregnancy: maternal plasma profiles during ovine gestation correlate with placental and fetal maturation. Endocrinology 2009; 150(10): 4777-4783.
30. Takei Y. Does the natriuretic peptide system exist throughout the animal and plant kingdom? Comp Biochem Physiol B Biochem Mol Biol 2001; 129(2-3): 559-573.
31. Inoue K, Naruse K, Yamagami S, Mitani H, Suzuki N, Takei Y. Four functionally distinct C-type natriuretic peptides found in fish reveal evolutionary history of the natriuretic peptide system. Proc Natl Acad Sci USA 2003; 100(17): 10079-10084.
32. Ogawa Y, Nakao K, Nakagawa O, et al. Human C-type natriuretic peptide. Characterization of the gene and peptide. Hypertension 1992; 19(6 Pt 2): 809-813.
33. Wu C, Wu F, Pan J, Morser J, Wu Q. Furin-mediated Processing of Pro-C-type Natriuretic Peptide. J Biol Chem 2003; 278(28): 25847-25852.
34. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002; 3(10): 753-766.
35. Villar IC, Panayiotou CM, Sheraz A, et al. Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarizing factor. Cardiovasc Res 2007; 74(3): 515-525.
36. Suga S, Nakao K, Itoh H, et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of vascular natriuretic peptide system. J Clin Invest 1992; 90(3): 1145-1149.
37. Suga S, Itoh H, Komatsu Y, et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells--evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology 1993; 133(6): 3038-3041.
38. Chun TH, Itoh H, Ogawa Y, et al. Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension 1997; 29(6): 1296-1302.
39. Hunt PJ, Richards AM, Espiner EA, Nicholls MG, Yandle TG. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab 1994; 78(6): 1428-1435.
40. Maack T, Suzuki M, Almeida FA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238(4827): 675-678.
41. Matsukawa N, Grzesik WJ, Takahashi N, et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA 1999; 96(13): 7403-7408.
42. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993; 291 (Pt 1): 83-88.
43. He X, Chow D, Martick MM, Garcia KC. Allosteric activation of a spring-loaded natriuretic peptide receptor dimer by hormone. Science 2001; 293(5535): 1657-1662.
44. Ogawa H, Qiu Y, Ogata CM, Misono KS. Crystal structure of hormone-bound atrial natriuretic peptide receptor extracellular domain: rotation mechanism for transmembrane signal transduction. J Biol Chem 2004; 279(27): 28625-28631.
45. Potter LR, Hunter T. Guanylyl cyclase-linked natriuretic peptide receptors: structure and regulation. J Biol Chem 2001; 276(9):6057-6060.
46. Murthy KS, Teng BQ, Zhou H, Jin JG, Grider JR, Makhlouf GM. G(i-1)/G(i-2)-dependent signaling by single-transmembrane natriuretic peptide clearance receptor. Am J Physiol Gastrointest Liver Physiol 2000; 278(6): G974-980.
47. Suga S, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992;130(1): 229-239.
48. Bennett BD, Bennett GL, Vitangcol RV, et al. Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J Biol Chem 1991; 266(34):23060-23067.
49. Koller KJ, Lowe DG, Bennett GL, et al. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 1991; 252(5002): 120-123.
50. Kone BC. Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc Res 2001; 51(3): 429-441.
51. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339(5): 321-328.
52. Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA, Garbers DL. Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci USA 2004; 101(49): 17300-17305.
53. Cohen D, Koh GY, Nikonova LN, Porter JG, Maack T. Molecular determinants of the clearance function of type C receptors of natriuretic peptides. J Biol Chem 1996; 271(16): 9863-9869.
54. Maack T. Receptors of atrial natriuretic factor. Annu Rev Physiol 1992; 54: 11-27.
55. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci 2002; 23(8): 374-380.
56. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A. Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation 2004; 110(10): 1231-1235.
57. Kun A, Kiraly I, Pataricza J, et al. C-type natriuretic peptide hyperpolarizes and relaxes human penile resistance arteries. J Sex Med 2008; 5(5): 1114-1125.
58. Scotland RS, Cohen M, Foster P, et al. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci USA 2005; 102(40): 14452-14457.
59. Furuya M, Aisaka K, Miyazaki T, et al. C-type natriuretic peptide inhibits intimal thickening after vascular injury. Biochem Biophys Res Commun 1993; 193(1): 248-253.
60. Ueno H, Haruno A, Morisaki N, et al. Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation 1997; 96(7): 2272-2279.
61. Wang Y, de Waard MC, Sterner-Kock A, et al. Cardiomyocyterestricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail 2007; 9(6-7): 548-557.
62. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004; 44(4): 398-404.
63. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008; 52(5): 818-827.
64. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010; 121(7): e46-e215.
65. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the american heart association professional education committee of the council for high blood pressure research. Hypertension 2008; 51(6): 1403-1419.
66. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370(9587): 591-603.
67. Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res 2009; 32(8): 1103-1108.
68. Okahara K, Kambayashi J, Ohnishi T, Fujiwara Y, Kawasaki T, Monden M. Shear stress induces expression of CNP gene in human endothelial cells. FEBS Lett 1995; 373(2): 108-110.
69. Ohno N, Itoh H, Ikeda T, et al. Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 2002; 105(14): 1623-1626.
70. Kuhnl A, Pelisek J, Tian W, et al. C-type natriuretic peptide inhibits constrictive remodeling without compromising reendothelialization in balloon-dilated renal arteries. J Endovasc Ther 2005; 12(2): 171-182.
71. Pelisek J, Fuchs AT, Kuehnl A, et al. C-type natriuretic peptide for reduction of restenosis: gene transfer is superior over single peptide administration. J Gene Med 2006; 8(7): 835-844.
72. Morishige K, Shimokawa H, Yamawaki T, et al. Local adenovirusmediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo. J Am Coll Cardiol 2000; 35(4): 1040-1047.
73. Ono K, Mannami T, Baba S, Tomoike H, Suga S, Iwai N. A singlenucleotide polymorphism in C-type natriuretic peptide gene may be associated with hypertension. Hypertens Res 2002; 25(5): 727-730.
74. Palmer SC, Prickett TC, Espiner EA, Yandle TG, Richards AM. Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension 2009; 54(3): 612-618.
75. Pitzalis MV, Sarzani R, Dessi-Fulgheri P, et al. Allelic variants of natriuretic peptide receptor genes are associated with family history of hypertension and cardiovascular phenotype. J Hypertens 2003; 21(8): 1491-1496.
76. Aoi N, Soma M, Nakayama T, et al. Variable number of tandem repeat of the 5'-flanking region of type-C human natriuretic peptide receptor gene influences blood pressure levels in obesity-associated hypertension. Hypertens Res 2004; 27(10): 711-716.
77. Caniffi C, Elesgaray R, Gironacci M, Arranz C, Costa MA. C-type natriuretic peptide effects on cardiovascular nitric oxide system in spontaneously hypertensive rats. Peptides 2010; 31(7): 1309-1318.
78. Yoshimoto T, Naruse M, Naruse K, et al. Vascular action of circulating and local natriuretic peptide systems is potentiated in obese/hyperglycemic and hypertensive rats. Endocrinology 1996; 137(12): 5552-5557.
79. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007 Sep 13; 357(11): 1121-1135.
80. Soeki T, Kishimoto I, Okumura H, et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 2005;45(4): 608-616.
81. Langenickel TH, Buttgereit J, Pagel-Langenickel I, et al. Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci USA 2006; 103(12): 4735-4740.
82. Tokudome T, Horio T, Soeki T, et al. Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-1 signaling pathways. Endocrinology 2004; 145(5): 2131-2140.
83. Horio T, Tokudome T, Maki T, et al. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 2003; 144(6): 2279-2284.
84. Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res 2003; 57(2):515-522.
85. Rose RA, Lomax AE, Kondo CS, Anand-Srivastava MB, Giles WR. Effects of C-type natriuretic peptide on ionic currents in mouse sinoatrial node: a role for the NPR-C receptor. Am J Physiol Heart Circ Physiol 2004; 286(5): H1970-H1977.
86. Simons M. Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? J Am Coll Cardiol 2005; 46(5): 835-837.
87. Simons M. Angiogenesis: where do we stand now? Circulation 2005; 111(12): 1556-1566.
88. Lekas M, Lekas P, Latter DA, Kutryk MB, Stewart DJ. Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation? Curr Opin Cardiol 2006;21(4): 376-384.
89. Sessa WC. Molecular control of blood flow and angiogenesis: role of nitric oxide. J Thromb Haemost 2009; 7 (Suppl 1): 35-37.
90. Doi K, Ikeda T, Itoh H, et al. C-type natriuretic peptide induces redifferentiation of vascular smooth muscle cells with accelerated reendothelialization. Arterioscler Thromb Vasc Biol 2001; 21(6):930-936.
91. Yamahara K, Itoh H, Chun TH, et al. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci USA 2003; 100(6): 3404-3409.
92. ten DP, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007;8(11): 857-869.
93. Ma J, Wang Q, Fei T, Han JD, Chen YG. MCP-1 mediates TGFbeta-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 2007; 109(3): 987-994.
94. Deckers MM, van Bezooijen RL, van der HG, et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 2002; 143(4):1545-1553.
95. Naruko T, Ueda M, van der Wal AC, et al. C-type natriuretic peptide in human coronary atherosclerotic lesions. Circulation 1996; 94(12): 3103-3108.
96. Naruko T, Itoh A, Haze K, et al. C-Type natriuretic peptide and natriuretic peptide receptors are expressed by smooth muscle cells in the neointima after percutaneous coronary intervention. Atherosclerosis 2005; 181(2): 241-250.
97. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American college of cardiology foundation/american heart association task force on practice guidelines developed in collaboration with the international society for heart and lung transplantation. J Am Coll Cardiol 2009; 53(15): e1-e90.
98. Boerrigter G, Burnett JC, Jr. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 2004;13(6): 643-652.
99. Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005; 115(3): 509-517.
100. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005; 97(7): 618-628.
101. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC, Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2008; 52(1): 60-68.
102. Lee CY, Chen HH, Lisy O, et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009; 49(6): 668-673.
103. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, Potter LR. Differential regulation of membrane guanylyl cyclases in congestive heart failure: NPR-B, not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 2007; 148(7):3518-3522.
104. Del RS, Cabiati M, Lionetti V, Emdin M, Recchia FA, Giannessi D. Expression of C-type natriuretic peptide and of its receptor NPR-B in normal and failing heart. Peptides 2008; 29(12): 2208-2215.
105. Del RS, Maltinti M, Piacenti M, Passino C, Emdin M, Giannessi D. Cardiac production of C-type natriuretic peptide in heart failure. J Cardiovasc Med (Hagerstown) 2006; 7(6): 397-399.
106. Kalra PR, Clague JR, Bolger AP, et al. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 2003; 107(4): 571-573.
107. Malcom GT, McMahan CA, McGill HC, Jr., et al. Associations of arterial tissue lipids with coronary heart disease risk factors in young people. Atherosclerosis 2009; 203(2): 515-521.
108. Shoenfeld Y, Sherer Y, Harats D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 2001;22(6): 293-395.
109. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2(2): 99-106.
110. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24(6): 1468-1474.
111. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340(2): 115-126.
112. Crowther MA. Pathogenesis of atherosclerosis. Hematology 2005; 2005(1): 436-441.
113. Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest 2005; 85(1): 9-23.
114. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol 2007; 49(25): 2379-2393.
115. Tsao PS, Buitrago R, Chan JR, Cooke JP. Fluid Flow Inhibits Endothelial Adhesiveness: Nitric Oxide and Transcriptional Regulation of VCAM-1. Circulation 1996; 94(7): 1682-1689.
116. Freedman JE, Sauter R, Battinelli EM, et al. Deficient plateletderived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res 1999; 84(12): 1416-1421.
117. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Aktdependent phosphorylation. Nature 1999; 399(6736): 601-605.
118. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399(6736): 597-601.
119. Ishizaka Y, Kangawa K, Minamino N, et al. Isolation and identification of C-type natriuretic peptide in human monocytic cell line, THP-1. Biochem Biophys Res Commun 1992; 189(2): 697-704.
120. Peltonen TO, Taskinen P, Soini Y, et al. Distinct downregulation of C-type natriuretic peptide system in human aortic valve stenosis. Circulation 2007; 116(11): 1283-12889.
121. Casco VH, Veinot JP, Kuroski de Bold ML, Masters RG, Stevenson MM, de Bold AJ. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 2002; 50(6): 799-809.
122. Sugiyama S, Kugiyama K, Matsumura T, et al. Lipoproteins regulate C-type natriuretic peptide secretion from cultured vascular endothelial cells. Arterioscler Thromb Vasc Biol 1995; 15(11): 1968-1974.
123. Kugiyama K, Sugiyama S, Matsumura T, Ohta Y, Doi H, Yasue H. Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC3.4.24.11). Arterioscler Thromb Vasc Biol 1996; 16(8): 1080-1087.
124. Chun TH, Itoh H, Saito T, et al. Oxidative stress augments secretion of endothelium-derived relaxing peptides, C-type natriuretic peptide and adrenomedullin. J Hypertens 2000; 18(5): 575-580.
125. Igaki T, Itoh H, Suga S, et al. Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide. Diabetes 1996; 45 (Suppl 3): S62-S64.
126. Yamashita J, Itoh H, Ogawa Y, et al. Opposite regulation of Gax homeobox expression by angiotensin II and C-type natriuretic peptide. Hypertension 1997; 29(1 Pt 2): 381-387.
127. Weir L, Chen D, Pastore C, Isner JM, Walsh K. Expression of gax, a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the proliferative response to balloon injury. J Biol Chem 1995; 270(10): 5457-5461.
128. Slottow TL, Waksman R. Drug-eluting stent safety. Am J Cardiol 2007; 100(8B): 10M-17M.
129. Jaffe R, Strauss BH. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. J Am Coll Cardiol 2007; 50(2): 119-127.
130. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007 Oct 2; 50(14): 1299-1304.
131. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115(17): 2344-2351.
132. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48(12): 2584-2591.
133. Matter CM, Rozenberg I, Jaschko A, et al. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2006; 48(6): 286-292.
134. Schwertz DW, Vaitkus P. Drug-eluting stents to prevent reblockage of coronary arteries. J Cardiovasc Nurs 2003; 18(1): 11-16.
135. Stahli BE, Camici GG, Tanner FC. Drug-eluting stent thrombosis. Ther Adv Cardiovasc Dis 2009; 3(1): 45-52.
136. Qian JY, Haruno A, Asada Y, et al. Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ Res 2002; 91(11): 1063-1069.
137. Gaspari TA, Barber MN, Woods RL, Dusting GJ. Type-C natriuretic peptide prevents development of experimental atherosclerosis in rabbits. Clin Exp Pharmacol Physiol 2000; 27(8): 653-655.
138. Fuchs AT, Kuehnl A, Pelisek J, et al. Inhibition of restenosis formation without compromising reendothelialization as a potential solution to thrombosis following angioplasty? Endothelium 2008; 15(1): 85-92.
139. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97(9): 916-931.
140. Bourassa MG. Long-term vein graft patency. Curr Opin Cardiol 1994; 9(6): 685-91.
141. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28(3): 616-626.
142. Hassantash SA, Bikdeli B, Kalantarian S, Sadeghian M, Afshar H. Pathophysiology of aortocoronary saphenous vein bypass graft disease. Asian Cardiovasc Thorac Ann 2008; 16(4): 331-336.
143. Schachner T, Zou Y, Oberhuber A, et al. Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts. Eur J Cardiothorac Surg 2004; 25(4):585-590.
144. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351(16): 1655-1665.
145. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109(2): 159-165.
146. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010; 121(18): 2045-2066.
147. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982; 66(2): 334-338.
148. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334(5): 296-302.
149. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358(9288): 1119-1123.
150. Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, et al. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102(4): 411-418.
151. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353(20):2148-2157.
152. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27(5):589-595.
153. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333(4): 214-221.
154. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159(6): 1925-1932.
155. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102(19): 2434-2440.
156. Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009; 121(1): 69-88.
157. Baliga RS, Zhao L, Madhani M, et al. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178(8):861-869.
158. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006; 129(2): 417-425.
159. Itoh T, Nagaya N, Murakami S, et al. C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 170(11): 1204-1211.
160. Klinger JR, Siddiq FM, Swift RA, et al. C-type natriuretic peptide expression and pulmonary vasodilation in hypoxia-adapted rats. Am J Physiol 1998; 275(4 Pt 1): L645-L652.
161. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009; (191):341-366.
162. Ahluwalia A, Hobbs AJ. Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor. Trends Pharmacol Sci 2005; 26(3): 162-167.
163. Del Ry S, Maltinti M, Piacenti M, Passino C, Emdin M, Giannessi D. Cardiac production of C-type natriuretic peptide in heart failure. J Cardiovasc Med (Hagerstown) 2006; 7(6): 397-399.
164. Hama N, Itoh H, Shirakami G, et al. Detection of C-type natriuretic peptide in human circulation and marked increase of plasma CNP level in septic shock patients. Biochem Biophys Res Commun 1994; 198(3): 1177-1182.
165. Totsune K, Takahashi K, Murakami O, Satoh F, Sone M, Mouri T. Elevated plasma C-type natriuretic peptide concentrations in patients with chronic renal failure. Clin Sci (Lond) 1994; 87(3): 319-322.
166. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375(9722): 1255-1266.